Senores Pharmaceuticals Ltd's Q1FY26 Quarterly Results

Result Summary

• Senores Pharmaceuticals Ltd reported a 35.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1FY26). On a year-on-year (YoY) basis, it witnessed a growth of 17350.6%.
• Its expenses for the quarter were down by 40.3% QoQ and up 16791.2% YoY.
• The net profit decreased 35.2% QoQ and increased 19154.5% YoY.
• The earnings per share (EPS) of Senores Pharmaceuticals Ltd stood at 4.6 during Q1FY26.

Financial Statments for Q1FY26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Senores Pharmaceuticals Ltd is a company operating in the pharmaceutical industry, primarily engaged in the development, manufacturing, and distribution of pharmaceutical products. The company focuses on providing high-quality, affordable medicines to improve patient outcomes. As a pharmaceutical company, Senores Pharmaceuticals likely offers a range of prescription and over-the-counter medications. While specific recent developments about the company are not provided in the data, the pharmaceutical industry is known for being highly regulated and competitive, with innovation and compliance being critical aspects of operations. The company's performance, as reflected in the financial data, may be influenced by factors such as market demand, regulatory approvals, and competitive pressures.

Revenue

In the first quarter of FY26, Senores Pharmaceuticals Ltd reported a total income of ₹141.35 crores. This represents a significant decrease of 35.0% quarter-over-quarter (QoQ) from the ₹217.34 crores recorded in the fourth quarter of FY25. However, when compared year-over-year (YoY) to the first quarter of FY25, where the income was a mere ₹0.81 crores, there is an extraordinary increase of 17350.6%. This massive YoY growth in revenue may suggest a substantial expansion or operational scale-up during the year, although specific reasons are not provided in the data. The revenue figures reflect the company's ability to generate sales and capture market opportunities within the pharmaceutical sector.

Profitability

The profitability metrics for Senores Pharmaceuticals Ltd reveal various changes over the periods compared. The profit before tax (PBT) for the first quarter of FY26 was ₹26.49 crores, marking an increase of 6.3% QoQ from ₹24.93 crores in the fourth quarter of FY25. The YoY increase is notable at 20276.9% compared to ₹0.13 crores in the first quarter of FY25. The tax expense for Q1FY26 was ₹5.31 crores, a significant shift from a tax benefit of ₹-7.77 crores in Q4FY25, resulting in a negative QoQ change of 168.3%. Profit after tax (PAT) for Q1FY26 decreased by 35.2% QoQ to ₹21.18 crores from ₹32.70 crores in Q4FY25, yet it shows a remarkable YoY growth of 19154.5% from ₹0.11 crores in Q1FY25. These figures illustrate the company's tax liabilities and net earnings performance over the periods assessed.

Operating Metrics

The earnings per share (EPS) for Senores Pharmaceuticals Ltd in Q1FY26 was ₹4.60, which shows a substantial decline of 62.3% QoQ from ₹12.20 in Q4FY25. However, the EPS increased by 35.3% YoY from ₹3.40 in Q1FY25. These EPS figures provide insight into the company's profitability on a per-share basis, reflecting the earnings available to shareholders. The financial data does not include specific details on other operational metrics such as production volumes or product-specific sales, but the provided EPS figures indicate the overall financial performance of the company from a shareholder perspective.